In one of our preliminary studies, an antihypertensive drug, hydralazine, a vasodilator without PPAR-γ agonistic action, reduced blood pressure levels, but CHF/CS was not ameliorated (data not shown). The gene discussed is PPARG; the disease is Cowden syndrome 1.